Answering big questions: Beatrice Mintz, Donald Pinkel, Baruch Blumberg, Irwin Rose

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Spotlight Article

Query Theory: A Tribute to Beatrice Mintz, PhD
By Fox Chase Cancer Center | May 4, 2021

Big questions. That’s what Beatrice Mintz, PhD, the former Jack Schultz Chair of Basic Science at Fox Chase Cancer Center, has dedicated her career to answering. Small questions, in her opinion, are not worth the time or effort. As a result of this philosophy—and through sheer force of personality—Mintz’s opus, according to Jonathan Chernoff, MD, Chief Scientific Officer at Fox Chase, contains the platforms of several fields, including developmental genetics, gene-transfer technology, epigenetics, and the tumor microenvironment.

“To pioneer in one major area of science is remarkable. But more? Otherworldly,” he says. An elected member of the National Academy of Sciences since 1973, Mintz, now 97, has collected scientific honors that are coveted, prestigious, and rare. But accolades were never the point. The point, Mintz says, is “simply the pursuit of a series of questions that I’ve enjoyed answering.”


Announcing the Donald Pinkel Archive

In collaboration with Donald Pinkel’s daughter, Mary Pinkel, the Cancer History Project is preserving and republishing materials from his personal archive. Pinkel, the founding director and CEO of St. Jude Children’s Research Hospital, is also celebrated by Roswell Park Comprehensive Cancer Center in the Cancer History Project.

Personal letters: Mixed reviews of Donald Pinkel’s article on Childhood Lymphocytic Leukemia
By Cancer History Project | May 6, 2021

In 1970, Donald Pinkel’s article, “Drug Dosage and Remission Duration in Childhood Lymphocytic Leukemia,” received mixed reviews. The paper, later published in Feb. 1971 in Cancer, was rejected by the Journal of Pediatrics. However, in a personal letter, Emil Frei lauds it as “an extremely important article.”

Both letters are reproduced here and available for download.

Primary source: Donald Pinkel’s June 1, 1986 Kettering Prize acceptance remarks
By Cancer History Project | May 6, 2021

There needs to be renewed enthusiasm and determination to extend nutrition and health services to all children in need, regardless of the socio-economic, ethnic, geographic or immigration status of their parents.

Donald Pinkel, June 1, 1986

Primary source: Donald Pinkel’s June 6, 1986 Kettering Prize remarks: Curing Children of Leukemia
By Cancer History Project | May 6, 2021


People


Institutions

National Breast Cancer Coalition Accomplishments and Milestones
By National Breast Cancer Coalition | May 7, 2021

Rutgers Cancer Institute’s 2019 redesignation: New Jersey’s only Comprehensive Cancer Center
By Rutgers Cancer Institute of New Jersey | May 4, 2021


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login